What does Ocular Therapeutix’s positive pre-NDA meeting mean for AXPAXLI approval?
Ocular Therapeutix keeps its AXPAXLI wet AMD NDA on track for Q4 after a positive FDA meeting, but OCUL still falls nearly 5%.
Pharma & Biotech
Pharma & Biotech
Can Samsung Bioepis reshape Europe’s retinal disease biosimilar market with OPUVIZ?
Find out how Samsung Bioepis’ OPUVIZ launch could reshape Europe’s aflibercept biosimilar market and ophthalmology access.